Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA
ORION CORPORATION PRESS RELEASE 20 APRIL 2026 at 16.00 EEST Orion Pharma’s ODM-212 Granted Orphan Drug Designation in Mesothelioma by the US FDA Orion Corporation (Orion Pharma) today announced that its investigational drug ODM-212 has received …